Dr. Slaoui had sat on the board of Moderna since 2017. Public officials, including Sen. Elizabeth Warren, D-Mass., have said his position with Moderna would have been a conflict of interest in his new role as head of COVID-19 vaccine development if he was incentivized to favor Moderna’s vaccine.
Moderna told Business Insider that Dr. Slaoui resigned from the board last week and that he will divest his $10 million in stock options.
Read the full article here.
More articles on pharmacy:
32 of 40 drugs deemed critical for COVID-19 in short supply
Gilead strikes deal to manufacture remdesivir for 127 countries
How Civica Rx has responded to drug shortages caused by COVID-19
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.